Results of Operations and Financial Condition. On July 29, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.…

The excerpt is incomplete and does not provide specific details about the event.

Results of Operations and Financial Condition. On May 7, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. Su…

Results of Operations and Financial Condition. On March 12, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.…

Entry into a Material Definitive Agreement. Background Between August 27, 2021 and October 26, 2021, four putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. These actions were filed in the U.S. District Court for the Western District of Texas (the “Texas District Court”). The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company's securit…

The filing details cash bonus awards for named executive officers, which is a compensatory arrangement and not a management change.

Results of Operations and Financial Condition. On November 12, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Secti…

Results of Operations and Financial Condition. On August 14, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section…

Other Events. On August 4, 2025, the Company announced positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of tuberous sclerosis complex (TSC)-related epilepsy. The study was conducted in collaboration with the TSC Alliance and the TSC Preclinical Consortium using an animal model of TSC-related epilepsy, the Tsc1 conditional knockout (CKO) mouse line ( Tsc1 -CKO). These mice develop spontaneous seizures and are used by the TSC Alliance to evaluate the e…

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

Results of Operations and Financial Condition. On May 8, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. Su…

Chief Medical Officer — James W. Kupiec, M.D.: Dr. James W. Kupiec retired as Chief Medical Officer.

The filing describes amendments to the Cash Incentive Bonus Plan, not a management change.

Results of Operations and Financial Condition. On March 3, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.…

Entry into a Material Definitive Agreement. On February 26, 2025, Cassava Sciences, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Yale University (“Yale”) pursuant to which the Company was granted exclusive worldwide rights, with rights to sublicense, to Yale’s interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of Tuberous Sclerosis Co…

shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.

by reference. Forward-Looking Statements This report contains forward-looking statements that include but are not limited to statements regarding: the planned discontinuation of the ReFocus-ALZ and open-label extension studies and the status of their ongoing wind-down; our intent to share detailed study results at a future medical meeting; the timing of anticipated milestones; the reduction in force of employees at the Company and the anticipated costs associated with the reduction in force.…

Costs Associated with Exit or Disposal Activities. On November 25, 2024, the Company reported that the topline results from its Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease did not meet its prespecified co-primary endpoints and announced the Company’s decision to discontinue its Phase 3 ReFocus-ALZ study and its open label extension study. In light of the foregoing, the Company today announced that it is reducing its workforce by 10 employees, a reduction of…

Results of Operations and Financial Condition. On November 7, 2024, the Registrant issued a press release announcing financial results for the quarter ended September 30, 2024, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “…

Executive Officer — Mr. Barry: The company entered into an executive employment agreement with Mr. Barry, providing significant compensation and benefits.

Other Events. On September 26, 2024, Cassava announced that it had reached a settlement with the U.S. Securities and Exchange Commission (the “SEC”) resolving the previously reported SEC investigation of the Company’s disclosures regarding its Phase 2b clinical trial of simufilam for the treatment of Alzheimer’s disease (the “Phase 2b Study”) and related matters. The SEC also agreed to a settlement with two former senior employees of the Company. The settlements with the Company and its forme…

CEO — Richard (Rick) Barry: Richard (Rick) Barry was promoted to CEO from Executive Chairman of the Board.

Results of Operations and Financial Condition. On August 8, 2024, the Company issued a press release announcing financial results for the quarter ended June 30, 2024 (the “Earnings Release”). Within the financial tables included in the Earnings Release, the Company incorrectly presented Net income (loss) per share, diluted for the Six months ended June 30, 2024 as $(1.72). The Company is filing this Amendment to provide the corrected Net income (loss) per share, diluted for the Six months end…

Results of Operations and Financial Condition. On August 8, 2024, the Registrant issued a press release announcing financial results for the quarter ended June 30, 2024, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchang…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 5, 2024, Cassava Sciences, Inc. (the “Company”) issued a press release regarding the passing of one of its long-time directors, Sanford Robertson on August 3, 2024. Mr. Robertson served as a member of the Audit Committee of the Company’s Board of Directors at the time of his death. Mr. Robertson’s death reduced the number of directors currently serving on the Company’s Audit Committe…